Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MegaNatural-BP claims supported

This article was originally published in The Tan Sheet

Executive Summary

Constellation Wines U.S./PolyPhenolics supports certain claims for its MegaNatural-BP dietary supplement, but should "clearly and conspicuously" communicate the supplement could be used as a part of a lifestyle management program by those with prehypertension and metabolic syndrome, the National Advertising Division states in an Oct. 14 decision. The advertiser submitted two clinical trials, which NAD says provide a reasonable basis for claims such as: "In the second study on participants with prehypertension, their systolic blood pressure dropped 8 mm and diastolic dropped 5 mm when taking 300 mg once per day for 2 months." The Council for Better Business Bureaus group recommends discontinuing the claim, "Provide relief with half the cost, half the dose and half the time," but says the advertiser can discuss the differences between MegaNatural-BP and antigen-converting enzyme inhibitors

You may also be interested in...

Faster Please: Alnylam, Eiger & BioCryst Want Quick EMA Reviews

Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.

Celltrion Healthcare Gears Up For Infliximab SC Launch

As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.

Congress Tackles Overpriced ‘Surprise’ Medical Bills, Taking Several Different Tacks

A trio of legislative proposals to lower high-cost “surprise” medical bills that limit what physicians and hospitals, labs, and imaging facilities can charge patients, emerged this winter from three different US congressional committees with health care jurisdiction. Check out our detailed chart that sorts out some of the provisions of the bills of interest to device and diagnostics firms.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts